Clinicopathologic Features and Response to Therapy of NRG1 Fusion–Driven Lung Cancers

home / between-the-lines / clinicopathologic-features-and-response-to-therapy-of-nrg1-fusion-driven-lung-cancers

Experts collaborate to share and reflect on data from an eNRGy1 global registry study, which analyzed therapy in NRG1 fusion–driven lung cancers.

EP. 1: NRG1 Fusion–Driven Lung Cancers: Clinicopathologic Features and Response to Therapy

Alexander Spira, MD, PhD, FACP;D. Ross Camidge, MD, PhD

October 8th 2021

A review of data from the eNRGy1 global registry study, with deference to the efficacy of current therapies and clinicopathologic features.

EP. 2: Key Takeaways From the eNRGy1 Global Multicenter Registry Study

Alexander Spira, MD, PhD, FACP;D. Ross Camidge, MD, PhD

October 15th 2021

Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, share insight and key takeaways from the eNRGy1 global registry study.

EP. 3: Considering the Role of NRG1 Fusions in Lung Cancer Management

Alexander Spira, MD, PhD, FACP;D. Ross Camidge, MD, PhD

October 22nd 2021

Practical considerations regarding the role of NRG1 fusions in lung cancer management and how that has been informed by the eNRGy1 global registry study.

EP. 4: NRG1 Fusion-Driven Lung Cancer: Future Directions in Care

Alexander Spira, MD, PhD, FACP;D. Ross Camidge, MD, PhD

October 29th 2021

Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, highlight the importance of global registries before sharing their closing thoughts on NRG1 fusions and the future treatment landscape of lung cancer.